: AERI

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. Take a look at the 1-year chart of Aerie (NASDAQ: AERI) below with my added notations: AERI has hit… Continue Reading »

Aerie Pharmaceuticals Inc (NASDAQ: AERI)

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.